Plain English information about the research being conducted on Parkinson's
# # # # This week the biotech firm Denali Therapeutics made two major announcements regarding the development of their LRRK2 inhibitor program for Parkinson’s. First, the company revealed that they have signed an agreement with the pharmaceutical company Biogen to co-develop and co-commercialise small molecule inhibitors of LRRK2 for Parkinson’s. Second, Denali also … Continue reading Billion dollar bets: Denali+Biogen
Biotech firm Denali announced the dosing of the first person in their Phase Ib clinical study of their experimental treatment for Parkinson’s called DNL201. DNL201 is an inhibitor of a Parkinson’s-associated protein called Leucine-rich repeat kinase 2 (LRRK2). In Parkinson’s, there is evidence that LRRK2 is over activate, and by inhibiting LRRK2 Denali is … Continue reading Denali: Phase Ib clinical trial starts
This week Denali Therapeutics released the results of a phase I clinical trial of their primary product, called DNL-201. DNL-201 is a LRRK2 inhibitor that the company is attempting to take to the clinic for Parkinson’s disease. In today’s post we will look at what LRRK2 is, how an inhibitor might help in Parkinson’s, and what … Continue reading Inhibiting LRRK2: The Denali Phase I results
# # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the … Continue reading 2020: Year in Review
# # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw … Continue reading Prevail lands on a Lilly pad
# # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New … Continue reading Monthly research review – October 2020
# # # # Over the past two decades, pharmaceutical companies have shifted from maintaining large in-house drug development platforms to a model that involves acquiring small biotech firms with interesting agents once those companies reach a certain point in their maturation. This week a biotech firm called Inflazome was bought by the big pharma … Continue reading When Inflazome becomes Roche
# # # # Transportation of material inside of cells is a critical aspect of normal cellular functioning. Any disruption to this activity can cause significant problems. An interesting aspect of recent genetic analysis work in Parkinson’s has been the number of genetic risk factors for the condition that are associated with cellular transportation activity. … Continue reading The world according to GARP
At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials … Continue reading Monthy research review – August 2020
At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials (Oooh, … Continue reading Monthly Research Review – May 2020
